Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Animals
Antibodies, Monoclonal, Humanized
/ chemistry
Carcinoma, Neuroendocrine
/ radiotherapy
Chelating Agents
/ chemistry
Humans
Intracellular Signaling Peptides and Proteins
/ antagonists & inhibitors
Ligands
Lutetium
Male
Membrane Proteins
/ antagonists & inhibitors
Mice
Pentetic Acid
/ chemistry
Prostatic Neoplasms
/ radiotherapy
Radioimmunotherapy
Radioisotopes
Xenograft Model Antitumor Assays
DLL3
lutetium-177
neuroendocrine prostate cancer
radioimmunotherapy
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
05 07 2022
05 07 2022
Historique:
entrez:
27
6
2022
pubmed:
28
6
2022
medline:
30
6
2022
Statut:
ppublish
Résumé
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer with limited meaningful treatment options. NEPC lesions uniquely express delta-like ligand 3 (DLL3) on their cell surface. Taking advantage of DLL3 overexpression, we developed and evaluated lutetium-177 (
Identifiants
pubmed: 35759660
doi: 10.1073/pnas.2203820119
pmc: PMC9271187
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Chelating Agents
0
DLL3 protein, human
0
Intracellular Signaling Peptides and Proteins
0
Ligands
0
Membrane Proteins
0
Radioisotopes
0
Lutetium
5H0DOZ21UJ
Pentetic Acid
7A314HQM0I
Lutetium-177
BRH40Y9V1Q
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2203820119Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM073546
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA232130
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA263816
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA213359
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA092629
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213448
Pays : United States
Références
Nat Rev Cancer. 2015 Jun;15(6):347-60
pubmed: 25998714
J Nucl Med. 2010 Mar;51(3):471-6
pubmed: 20197451
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
Transl Oncol. 2020 Sep;13(9):100801
pubmed: 32460182
J Thorac Oncol. 2021 Sep;16(9):1547-1558
pubmed: 33607312
J Thorac Oncol. 2021 Sep;16(9):1570-1581
pubmed: 33823285
Life Sci. 2019 Jun 1;226:149-155
pubmed: 30981764
Sci Transl Med. 2019 Mar 20;11(484):
pubmed: 30894499
NPJ Precis Oncol. 2021 Aug 5;5(1):74
pubmed: 34354225
Clin Cancer Res. 2019 Jan 1;25(1):210-221
pubmed: 30327311
J Thorac Oncol. 2020 Apr;15(4):520-540
pubmed: 32018053
J Nucl Med. 2022 Jan 20;:
pubmed: 35058323
Cell Rep. 2016 Aug 2;16(5):1259-1272
pubmed: 27452466
Science. 2017 Jan 6;355(6320):78-83
pubmed: 28059767
Sci Transl Med. 2015 Aug 26;7(302):302ra136
pubmed: 26311731
J Cell Biol. 2007 Jul 30;178(3):465-76
pubmed: 17664336
Eur J Cancer. 2019 Nov;121:7-18
pubmed: 31525487
Cancer Res. 2017 Jul 15;77(14):3931-3941
pubmed: 28487384
Endocr Relat Cancer. 2021 Jul 15;28(8):T67-T78
pubmed: 34111024
J Nucl Med. 2019 Dec;60(12):1802-1811
pubmed: 31201251
Clin Cancer Res. 2022 Apr 1;28(7):1391-1401
pubmed: 35046060
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Nucl Med Biol. 2009 Oct;36(7):729-39
pubmed: 19720285
Clin Cancer Res. 2019 Dec 1;25(23):6958-6966
pubmed: 31506387